Henk Streefkerk
Henk is an MD PhD with +15 years in Pharma, leading development of drugs from discovery to market. He contributed significantly to the approval of several global medications used by thousands of patients (e.g. Rasitrio, Entresto, Kisqali).
He has held multiple medical roles in large Pharmaceuticals (Organon, Novartis) as well as Biotechs (Actelion, PIQUR, NarrowRiver), in translational medicine, safety, and clinical development in cardiovascular, oncology, and orphan diseases. Most recently, he was CMO of an Oncology Biotech in Basel. He is a consultant CMO and Drug Safety Officer for various biotech companies in the US and Europe.
Interesting Fact:
Created 3D animations of neurosurgical operations that were broadcasted across clinics, NBC and Dutch media. Loves to build remote controlled helicopters and fly them.
Publications by Henk Streefkerk
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
Oncologist . 2022 Dec 9;27(12):1004-e926. · Dec 9, 2022
Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial
Cancers · Mar 15, 2022
A Database Cohort Study to Assess the Risk of AngioedemaAmong Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA
Am J Cardiovasc Drugs · Nov 24, 2017
Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM
Drug Saf (2017). doi:10.1007/s40264-017-0541-2 · May 15, 2017
Normal response of cardiac flow and function to adenosine stress as assessed by cardiac MR.
J Cardiovasc Med (Hagerstown). 2012 Aug 8. [Epub ahead of print] · Aug 8, 2012
The excimer laser-assisted nonocclusive anastomosis practice model: development and application of a tool for practicing microvascular anastomosis techniques.
Neurosurgery. 2006 Feb;58(1 Suppl):ONS148-56; discussion ONS148-56. · Feb 1, 2006